The 10-second takeaway
For the quarter ended March 31 (Q1), Stericycle met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded. Non-GAAP earnings per share increased. GAAP earnings per share expanded.
Gross margins shrank, operating margins were steady, net margins grew.
Stericycle booked revenue of $513.8 million. The 12 analysts polled by S&P Capital IQ anticipated sales of $520.1 million on the same basis. GAAP reported sales were 12% higher than the prior-year quarter's $460.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.88. The 15 earnings estimates compiled by S&P Capital IQ averaged $0.88 per share. Non-GAAP EPS of $0.88 for Q1 were 13% higher than the prior-year quarter's $0.78 per share. GAAP EPS of $0.85 for Q1 were 13% higher than the prior-year quarter's $0.75 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 45.2%, 170 basis points worse than the prior-year quarter. Operating margin was 26.2%, much about the same as the prior-year quarter. Net margin was 14.5%, 40 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $530.9 million. On the bottom line, the average EPS estimate is $0.91.
Next year's average estimate for revenue is $2.13 billion. The average EPS estimate is $3.69.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 298 members out of 326 rating the stock outperform, and 28 members rating it underperform. Among 95 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 86 give Stericycle a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stericycle is outperform, with an average price target of $106.38.
Looking for alternatives to Stericycle? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Stericycle to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends Stericycle. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Stericycle Inc. Stumbled Backwards in Q3
The medical waste disposal and secure information destruction company announced a business transformation to turn around its financial performance.
Organic Growth Pushes Stericycle Inc's Revenue Higher
The medical waste disposal specialist proposed a settlement to a class action lawsuit that should put that matter in the rearview mirror.
Stericycle Inc: Buy the Dip?
Shares are trading near 52-week lows. Does that represent a buying opportunity for Stericycle stock?